Adlai Nortye Ltd.
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
ANL | NDAQ
Overview
Corporate Details
- ISIN(s):
- US00704R1095
- LEI:
- Country:
- United States of America
- Address:
- 685 U.S. HIGHWAY ONE, 2ND FLOOR, 8902 NORTH BRUNSWICK
- Website:
- https://www.adlainortye.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Adlai Nortye Ltd. is a global clinical-stage biopharmaceutical company focused on the discovery and development of differentiated, innovative cancer therapies. Specializing in targeted and immune-modulating treatments, the company advances a robust oncology pipeline. Key candidates include AN8025, a trifunctional fusion protein designed to modulate T cells and antigen-presenting cells; AN9025, an oral small molecule pan-RAS(ON) inhibitor; and AN4005, an oral small molecule PD-L1 inhibitor. The company operates global research and development centers in the U.S. and China.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Adlai Nortye Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Adlai Nortye Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Adlai Nortye Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
